Reports
Reports
Analyst Viewpoint
Increase in demand for generic drugs, rise in need for cost-effective healthcare solutions, and growth in prevalence of chronic diseases are fueling the market growth. Furthermore, surge in cost of branded drugs and the need for more affordable healthcare options are offering lucrative sterile injectable drugs market opportunities for manufacturers of generic drugs, including generic injectables.
Key players need to increase investments in the research of innovative drug delivery systems and the development of cost-effective generic injectable drugs with increased efficacy with reduced adverse reactions. Furthermore, increase in government expenditure on the healthcare sector, surge in technological advancements, and increase in research and development activities by major players are anticipated to boost the global demand for sterile injectable drugs in the near future.
Sterile injectable are drugs and other therapeutic products that are injected directly into bloodstream or human tissues. In contrast to non-sterile medications such as tablets, gets, or sprays, sterile injectable bypass the body’s inherent defense mechanisms. These types of medications can be quite effective, but can also increase the risk of infection from the product to patient.
Consequently, sterile injectables must be kept free from microorganisms or other contaminants that could harm the patient. Therefore, strict regulations enacted by governments ensure all guidelines are followed at the production facilities and during the manufacturing processes of these medications.
These medications can be challenging to administer; however they have rapid rate of absorption, and eliminate the possibility of a first-pass effect. Subcutaneous injections, intramuscular injections, intravenous injections, intraperitoneal injections, intraosseous injection, intracardiac injections, intraarticular injections and intracavernous injections are the different types of injectables used.
Increase in research & development efforts as well as rise in investment from pharmaceutical companies to create improved injectable drugs including anti-infective, oncolytic, and cardiovascular drugs is driving the sterile injectable solutions market. Moreover, surge in number of major companies working together to produce an extensive array of high-quality vital medications as well as rise in incidence of chronic conditions such as cancer is propelling the need for cutting-edge treatment alternatives for various types of cancer.
Vendors of sterile injectable drugs need significant capital investments to automate the manufacturing process and boost efficiency. Several companies around the globe are engaging in mergers and acquisitions to favorable government policies and geographical conditions. For instance, in July 2019, Nexus Pharmaceuticals invested US$250 Mn to expand its Wisconsin factory, which is expected to meet the demand for sterile injectables in numerous fields such as neurology, oncology, cardiovascular, and anesthesia.
Rise in number of cases of chronic diseases and conditions, such as diabetes, heart disease and various forms of cancer, around the world is anticipated to boost the demand for sterile injectable drugs during the forecast period. In December 2021, the International Diabetes Federation reported that in the year 2021, 32.2 million people in the U.S. had diabetes, and the number is projected to reach 57 million by 2030.
Increase in number of pharmaceutical companies focusing on the development of novel medications to treat cancer is also estimated to fuel the demand for sterile injectable therapeutics. Additionally, rapid clearance of sterile injectable medications by the FDA combined with the shorter approval processes for novel treatments being developed to treat cancer is improving access to drugs and eventually driving the sterile injectable drugs market demand across the world.
Rise in geriatric population is driving the need for injectable drugs, as they are often prescribed for elderly patients. Furthermore, increase in demand for cost-effective pharmaceutical products and rise in adoption of generic medicines due to their affordability and accessibility are anticipated to propel the demand for injectable drugs in the near future. These generic sterile injectables are preferred by patients and healthcare professionals as an affordable alternative for treatments.
According to latest region-wise sterile injectable drugs market insights, increase in prevalence of chronic diseases such as cancer, diabetes and cardiovascular disease, as well as robust healthcare infrastructure and presence of key players are driving the growth of the sterile injectable drugs industry in North America. Moreover, increase in number of product launches, substantial R&D expenditures, and surge in utilization of sterile injectable drugs in healthcare facilities are also contributing to the prominent market share of the region.
The American Cancer Society's 2022 report projected that more than 1.9 million new cases of cancer would be diagnosed in the U.S. in 2022. The same source also stated that the risk of cancer increases with age. In the U.S., 80% of cancer patients are 55 years of age or older, and 57% are 65 years of age or older. Consequently, rise in aging population in North America is anticipated to have significantly influence the sterile injectable drugs market outlook for the region in the next few years.
Increase in investments in research, partnerships, and strategic collaborations is projected to boost the launch of new sterilized injectable medications and applications of sterile injectable drugs for effective treatments of chronic illnesses. For instance, in May 2022, Roche introduced PHESGO, a combination of Herceptin (trastuzumab) and Perjeta (pertuzumab) with hyaluronidase, to treat breast cancer.
In February 2022, the US Food and Drug Administration (FDA) authorized Takeda's TAKHZYRO injectable single-dose prefilled syringe (PFS) for lanadelumab-flyo in order to prevent attacks and pediatric patients 12 years of age and older against hereditary angioedema (HAE) attacks.
Analysis of the latest sterile injectable drugs market scenario reveals that Leading players are following the latest market trends and adopting advances in technology, such as improvements in manufacturing processes and the development of innovative drug delivery systems to consolidate their position in the global business. Moreover, the global business is highly competitive owing to the presence of numerous generic drug manufacturers competing for market share. A few of the key players operating in the global sterile injectable drugs industry are Baxter International, Sanofi S.A, Pfizer, Inc., GlaxoSmithKline Plc., AstraZeneca, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., Novo Nordisk A/S, Gilead Sciences, Inc.
Key players in the sterile injectable drugs market report have been profiled based on various parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 584.6 Bn |
| Market Forecast (Value) in 2031 | US$ 909.4 Bn |
| Growth Rate (CAGR) | 4.9% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional-level analysis. Furthermore, the qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 584.6 Bn in 2022
It is anticipated to expand at a CAGR of 4.9% from 2023 to 2031
Rise in investments by key players and increase in prevalence of chronic diseases
In terms of drug class, the monoclonal antibodies (Mabs) segment held largest share in 2022
North America was leading region in 2022
Baxter International, Sanofi S.A, Pfizer, Inc., GlaxoSmithKline Plc., AstraZeneca, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., Novo Nordisk A/S, Gilead Sciences, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sterile Injectable Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Sterile Injectable Drugs Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Type/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Sterile Injectable Drugs Market Analysis and Forecast, by Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Small Molecule
6.3.2. Large Molecule
6.4. Market Attractiveness, by Type
7. Global Sterile Injectable Drugs Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Class, 2017–2031
7.3.1. Monoclonal Antibodies (Mabs)
7.3.2. Cytokines
7.3.3. Insulin
7.3.4. Peptide Hormones
7.3.5. Vaccine
7.3.6. Immunoglobulins
7.3.7. Blood Factors
7.3.8. Peptide Antibiotics
7.3.9. Others
7.4. Market Attractiveness, by Drug Class
8. Global Sterile Injectable Drugs Market Analysis and Forecast, by Indication
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2017–2031
8.3.1. Cardiology & Metabolic Disorders
8.3.2. Neurology
8.3.3. Oncology
8.3.4. Autoimmune
8.3.5. Gastroenterology
8.3.6. Hematology
8.3.7. Pain
8.3.8. Infectious Disease
8.3.9. Others
8.4. Market Attractiveness, by Indication
9. Global Sterile Injectable Drugs Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. E-commerce
9.4. Market Attractiveness, by Distribution Channel
10. Global Sterile Injectable Drugs Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Sterile Injectable Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Small Molecule
11.2.2. Large Molecule
11.3. Market Attractiveness, by Type
11.4. Market Value Forecast, by Drug Class, 2017–2031
11.4.1. Monoclonal Antibodies (Mabs)
11.4.2. Cytokines
11.4.3. Insulin
11.4.4. Peptide Hormones
11.4.5. Vaccine
11.4.6. Immunoglobulins
11.4.7. Blood Factors
11.4.8. Peptide Antibiotics
11.4.9. Others
11.5. Market Attractiveness, by Drug Class
11.6. Market Value Forecast, by Indication, 2017–2031
11.6.1. Cardiology & Metabolic Disorders
11.6.2. Neurology
11.6.3. Oncology
11.6.4. Autoimmune
11.6.5. Gastroenterology
11.6.6. Hematology
11.6.7. Pain
11.6.8. Infectious Disease
11.6.9. Others
11.7. Market Attractiveness, by Indication
11.8. Market Value Forecast, by Distribution Channel, 2017–2031
11.8.1. Hospital Pharmacy
11.8.2. Retail Pharmacy
11.8.3. E-commerce
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Type
11.11.2. By Drug Class
11.11.3. By Indication
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Sterile Injectable Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Small Molecule
12.2.2. Large Molecule
12.3. Market Attractiveness, by Type
12.4. Market Value Forecast, by Drug Class, 2017–2031
12.4.1. Monoclonal Antibodies (Mabs)
12.4.2. Cytokines
12.4.3. Insulin
12.4.4. Peptide Hormones
12.4.5. Vaccine
12.4.6. Immunoglobulins
12.4.7. Blood Factors
12.4.8. Peptide Antibiotics
12.4.9. Others
12.5. Market Attractiveness, by Drug Class
12.6. Market Value Forecast, by Indication, 2017–2031
12.6.1. Cardiology & Metabolic Disorders
12.6.2. Neurology
12.6.3. Oncology
12.6.4. Autoimmune
12.6.5. Gastroenterology
12.6.6. Hematology
12.6.7. Pain
12.6.8. Infectious Disease
12.6.9. Others
12.7. Market Attractiveness, by Indication
12.8. Market Value Forecast, by Distribution Channel, 2017–2031
12.8.1. Hospital Pharmacy
12.8.2. Retail Pharmacy
12.8.3. E-commerce
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Type
12.11.2. By Drug Class
12.11.3. By Indication
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Sterile Injectable Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Small Molecule
13.2.2. Large Molecule
13.3. Market Attractiveness, by Type
13.4. Market Value Forecast, by Drug Class, 2017–2031
13.4.1. Monoclonal Antibodies (Mabs)
13.4.2. Cytokines
13.4.3. Insulin
13.4.4. Peptide Hormones
13.4.5. Vaccine
13.4.6. Immunoglobulins
13.4.7. Blood Factors
13.4.8. Peptide Antibiotics
13.4.9. Others
13.5. Market Attractiveness, by Drug Class
13.6. Market Value Forecast, by Indication, 2017–2031
13.6.1. Cardiology & Metabolic Disorders
13.6.2. Neurology
13.6.3. Oncology
13.6.4. Autoimmune
13.6.5. Gastroenterology
13.6.6. Hematology
13.6.7. Pain
13.6.8. Infectious Disease
13.6.9. Others
13.7. Market Attractiveness, by Indication
13.8. Market Value Forecast, by Distribution Channel, 2017–2031
13.8.1. Hospital Pharmacy
13.8.2. Retail Pharmacy
13.8.3. E-commerce
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Type
13.11.2. By Drug Class
13.11.3. By Indication
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Sterile Injectable Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Small Molecule
14.2.2. Large Molecule
14.3. Market Attractiveness, by Type
14.4. Market Value Forecast, by Drug Class, 2017–2031
14.4.1. Monoclonal Antibodies (Mabs)
14.4.2. Cytokines
14.4.3. Insulin
14.4.4. Peptide Hormones
14.4.5. Vaccine
14.4.6. Immunoglobulins
14.4.7. Blood Factors
14.4.8. Peptide Antibiotics
14.4.9. Others
14.5. Market Attractiveness, by Drug Class
14.6. Market Value Forecast, by Indication, 2017–2031
14.6.1. Cardiology & Metabolic Disorders
14.6.2. Neurology
14.6.3. Oncology
14.6.4. Autoimmune
14.6.5. Gastroenterology
14.6.6. Hematology
14.6.7. Pain
14.6.8. Infectious Disease
14.6.9. Others
14.7. Market Attractiveness, by Indication
14.8. Market Value Forecast, by Distribution Channel, 2017–2031
14.8.1. Hospital Pharmacy
14.8.2. Retail Pharmacy
14.8.3. E-commerce
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Type
14.11.2. By Drug Class
14.11.3. By Indication
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Sterile Injectable Drugs Market ;Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017–2031
15.2.1. Small Molecule
15.2.2. Large Molecule
15.3. Market Attractiveness, by Type
15.4. Market Value Forecast, by Drug Class, 2017–2031
15.4.1. Monoclonal Antibodies (Mabs)
15.4.2. Cytokines
15.4.3. Insulin
15.4.4. Peptide Hormones
15.4.5. Vaccine
15.4.6. Immunoglobulins
15.4.7. Blood Factors
15.4.8. Peptide Antibiotics
15.4.9. Others
15.5. Market Attractiveness, by Drug Class
15.6. Market Value Forecast, by Indication, 2017–2031
15.6.1. Cardiology & Metabolic Disorders
15.6.2. Neurology
15.6.3. Oncology
15.6.4. Autoimmune
15.6.5. Gastroenterology
15.6.6. Hematology
15.6.7. Pain
15.6.8. Infectious Disease
15.6.9. Others
15.7. Market Attractiveness, by Indication
15.8. Market Value Forecast, by Distribution Channel, 2017–2031
15.8.1. Hospital Pharmacy
15.8.2. Retail Pharmacy
15.8.3. E-commerce
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Type
15.11.2. By Drug Class
15.11.3. By Indication
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Baxter International
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Type Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Sanofi S.A
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Type Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Pfizer, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Type Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. GlaxoSmithKline Plc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Type Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. AstraZeneca
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Type Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Merck & Co., Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Type Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Novartis AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Type Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Johnson & Johnson Services, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Type Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Novo Nordisk A/S
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Type Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Gilead Sciences, Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Type Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
List of Tables
Table 01: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 03: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 05: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 08: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 09: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 10: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 13: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 14: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 15: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 18: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 19: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 20: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 23: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 24: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 25: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 28: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 29: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 30: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Sterile Injectable Drugs Market Size (US$ Mn), by Region, 2022 and 2031
Figure 02: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Type, 2022
Figure 03: Global Sterile Injectable Drugs Market Value Share, by Type, 2022
Figure 04: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Drug Class, 2022
Figure 05: Global Sterile Injectable Drugs Market Value Share, by Drug Class, 2022
Figure 06: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Indication, 2022
Figure 07: Global Sterile Injectable Drugs Market Value Share, by Indication, 2022
Figure 08: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 09: Global Sterile Injectable Drugs Market Value Share, by Distribution Channel, 2022
Figure 10: Global Sterile Injectable Drugs Market Value Share, by Region, 2022
Figure 11: Global Sterile Injectable Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 12: Global Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 13: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
Figure 14: Global Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 15: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 16: Global Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 17: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 18: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 19: Global Sterile Injectable Drugs Market Value Share, by Distribution Channel, 2022
Figure 20: Global Sterile Injectable Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 21: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Region, 2023-2031
Figure 22: North America Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 23: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Country, 2023–2031
Figure 24: North America Sterile Injectable Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 25: North America Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 26: North America Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 27: North America Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 28: North America Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 29: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023–2031
Figure 30: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 31: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 32: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 33: Europe Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 34: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 35: Europe Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Europe Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 37: Europe Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 38: Europe Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 39: Europe Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 40: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023–2031
Figure 41: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 42: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 43: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 44: Asia Pacific Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 45: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 46: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 47: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 48: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 49: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 50: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023–2031
Figure 52: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 53: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 54: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 55: Latin America Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 56: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 57: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 58: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 59: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 60: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 61: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 62: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023–2031
Figure 63: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 64: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 65: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 66: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 67: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 68: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 69: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
Figure 70: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 71: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 72: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 73: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023–2031
Figure 74: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 75: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 76: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Sterile Injectable Drugs Market